FTC Denies Violations In Watson Pay-To-Delay Probe
The Federal Trade Commission argued Thursday that it did nothing wrong in its antitrust investigation of a patent settlement between Watson Pharmaceuticals Inc. and Cephalon Inc., in a suit seeking to...To view the full article, register now.
Already a subscriber? Click here to view full article